- Home
- AGL vs TNDM Comparison
AGL vs TNDM Comparison
Compare AGL & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- TNDM
- Stock Information
- Founded
- AGL 2016
- TNDM 2006
- Country
- AGL United States
- TNDM United States
- Employees
- AGL N/A
- TNDM N/A
- Industry
- AGL Managed Health Care
- TNDM Medical/Dental Instruments
- Sector
- AGL Health Care
- TNDM Health Care
- Exchange
- AGL Nasdaq
- TNDM Nasdaq
- Market Cap
- AGL 952.1M
- TNDM 1.1B
- IPO Year
- AGL 2021
- TNDM 2013
- Fundamental
- Price
- AGL $1.10
- TNDM $12.52
- Analyst Decision
- AGL Hold
- TNDM Buy
- Analyst Count
- AGL 20
- TNDM 16
- Target Price
- AGL $3.03
- TNDM $23.50
- AVG Volume (30 Days)
- AGL 7.3M
- TNDM 1.8M
- Earning Date
- AGL 11-06-2025
- TNDM 11-05-2025
- Dividend Yield
- AGL N/A
- TNDM N/A
- EPS Growth
- AGL N/A
- TNDM N/A
- EPS
- AGL N/A
- TNDM N/A
- Revenue
- AGL $5,901,182,000.00
- TNDM $1,001,719,000.00
- Revenue This Year
- AGL N/A
- TNDM $8.27
- Revenue Next Year
- AGL $7.04
- TNDM $9.72
- P/E Ratio
- AGL N/A
- TNDM N/A
- Revenue Growth
- AGL 11.76
- TNDM 25.84
- 52 Week Low
- AGL $0.71
- TNDM $9.98
- 52 Week High
- AGL $6.08
- TNDM $47.60
- Technical
- Relative Strength Index (RSI)
- AGL 37.45
- TNDM 47.73
- Support Level
- AGL $1.03
- TNDM $12.10
- Resistance Level
- AGL $1.29
- TNDM $13.18
- Average True Range (ATR)
- AGL 0.10
- TNDM 0.57
- MACD
- AGL 0.01
- TNDM 0.23
- Stochastic Oscillator
- AGL 17.60
- TNDM 56.58
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.